EVMN · Evommune, Inc.
$11.25
-0.22 (-1.92%)
At close · Jul 28
Market Cap
$413.13M
Shares
36.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.25
Open$11.44
Day$11.04–11.81
52W$10.47–33.20
Avg vol 30d1.1M
Short int4.0M · 11.2% float · 3.7d
Short vol16%
Last earningsMar 5, 2026
DataNov 2025–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−38%
below
RSI (14)
32
neutral
MACD trend
Positive
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−55%
trailing
6-month return
−42%
trailing
YTD return
−34%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
5 of 83 funds reported for Jun 30 · net -482.0K sh shares · +2 new
Insider flow
Distributing
Net -$1.5M over 90 days · 71% sells
Short interest
Falling
11.15% of float · ▼ -15.9% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — 13F breadth
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+86%
Y/Y
EPS growth
+75%
Y/Y
Free cash flow
$-76.7M
Balance sheet
$44.1M
net cash
Quant / Vol
risk profile
Volatility
131%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−38%
Bearish
RSI (14)
32
Neutral
MACD trend
Positive
Bullish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
5 of 83 funds reported for Jun 30 · net -482.0K sh shares · +2 new
Insider flow
Distributing
Net -$1.5M over 90 days · 71% sells
Short interest
Falling
11.15% of float · ▼ -15.9% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $10
Now $11 · 3%
52-wk high $33
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EVMN
this stock
Evommune, Inc.
|
$413.13M | -34.3% | +85.7% | — | 11.2% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EVMN | -2.4% | -55.3% | -41.5% | -15.4% | -34.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.4% | -55.3% | -48.9% | -14.6% | -42.9% |